Morgan Stanley Downgrades Gen-Probe (GPRO) to Equalweight
More News related to GPRO
- ThinkEquity Initiates Coverage on Gen-Probe (GPRO) with a Buy
- DiagnoCure announces second quarter financial results
- Gen-Probe to Webcast Two Upcoming Investor Presentations
- DiagnoCure to host Q2 2009 earnings conference call and webcast
- Gen-Probe (GPRO) Appoints Carl W. Hull as CEO
Morgan Stanley downgrades Gen-Probe (Nasdaq: GPRO) from Overweight to Equalweight.
Gen-Probe Incorporated (Gen-Probe) is engaged in the development, manufacture and marketing of nucleic acid probe-based products used for the clinical diagnosis of human diseases and for screening donated human blood.
Related Categories
DowngradesStocks Mentioned
-1.38Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
